Close Menu

Bayer

Data presented at ESMO showed that in 175 adults and children with more than 20 kinds of tumors the drug on average can stave off progression for more than three years.

Patients with metastatic solid tumors who are ineligible for surgical resection and who are out of treatment options meet the criteria for testing within the FastTRK program.

Given the rarity of NTRK fusions, the company is also rolling out a free testing program to identify NTRK fusion-positive patients who would benefit from treatment.

In ASCO studies, one PI3K inhibitor showed efficacy in PIK3CA-mutated breast cancer patients progressing on CDK4/6 inhibitors, while the other yielded less encouraging signals.

The authors of a recently published study suggested that testing metastatic breast cancer patients for kinase fusions may open up additional treatment opportunities.

The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.

The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.

The analysis presented at the AACR Virtual Annual Meeting confirmed the effectiveness of the TRK inhibitor to treat cancer patients with NTRK gene fusions.

Under the deal, the companies aim to develop a companion diagnostic for Bayer's solid tumor drug larotrectinib for the Chinese market.

NICE reversed an earlier decision and issued a positive recommendation after Bayer discounted the price of the drug.

Pages